A comparative study of patients with methicillin susceptible versus methicillin resistant Staphylococcus aureus bacteremia: Epidemiology and prognostic factors;Estudio comparativo de pacientes con bacteremia por Staphylococcus aureus sensible a la meticilina frente a S. aureus resistente a la meticilina: Epidemiología y factores pronósticos

Medicina Clinica

Volumn 128, Issue 18, 2007, Pages 681-686

  García Vázquez, Elisa ^a   Gómez, Joaquín ^a   Baños, Ramón ^a   Canteras, Manuel ^b   Ruiz, Joaquín ^a   Baños, Victor ^a   Herrero, José Antonio ^a   Valdés, Mariano ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Bacteremia; Methicillin; Methicillin resistance; Methicillin sensitivity; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ARTICLE; BACTEREMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PROSPECTIVE STUDY; RISK FACTOR;

EID: 34347244567     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13102350     Document Type: Article

References (38)

1. Broseta A, Chaves F, Rojo P, Otero JR. Emergencia de un clon de Staphylococcus aureus resistente a meticilina de origen comunitario en la población pediátrica del sur de Madrid. Enferm Infecc Microbiol Clin. 2006;24:31-5.
2. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005;41:S269-72.
3. Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, et al; European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis. 2004;10:1627-34.
4. Oteo J, Cruchaga S, Campos J, Sáez JA, Baquero F, y miembros españoles del Grupo del European Antimicrobial Resistance Surveillance System (EARSS). Resistencia a los antibióticos en Staphylococcus aureus aislados de sangre en 31 hospitales españoles de la Red Europea de Vigilancia de Resistencia a Antibióticos (2000). Med Clin (Barc). 2002;119:361-5.
5. Sopena N, Sabrià M. Staphylococcus aureus resistente a la meticilina. Med Clin (Barc). 2002;118:671-6.
6. Cosgrove SE, Sakoulas G, Perencevich EN, Schawer MJ, Karchmer AW. Comparison of mortality associated with meticillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis. 2003;36:53-9.
7. Soriano A, Martínez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2000;30:368-73.
8. Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicenter study of Staphylococcus aureus bacteremia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine. 2003;82:322-32.
9. Games JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-40.
10. Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteraemia. Arch Intern Med. 1984;144:541-5.
11. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, et al. Infective endocarditis. Diagnosis, antimicrobial therapy, and management of complications. Circulation. 2005;111:e394-e433.
12. McCabe WR, Jackson GG. Gram negative bacteremia. Etiology and ecology. Arch Intern Med. 1962;110:847-55.
13. Winston DJ, Murphy W, Young LS, Hewitt WL. Piperacillin therapy for serious bacterial infections. Am J Med. 1980;69:255-61.
14. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin Infect Dis. 2006;42:234-6.
15. Fowler VG Jr, Justice A, Moore C, Benjamin DK Jr, Woods CW, Campbell S, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:695-703.
16. Duckworth GJ, Jordens JZ. Adherence and survival properties of an epidemic methicillin-resistant strain of Staphylococcus aureus compared with those of methicillin sensitive strains. J Med Microbiol. 1990;32:195-200.
17. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med. 1998;158:182-9.
18. Catchpole C, Wise R, Fraise A. MRSA bacteremia. J Hosp Infect. 1997;35:159-61.
19. Conterno LO, Wey SB, Costelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 1998;19:32-7.
20. Blot S, Vandewoude K, Hoste E, Colardyn F. Attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Inter Med. 2002;162:2229-35.
21. Zahar JR, Clec'h C, Tafflet M, Garrouste-Orgeas M, Jamali S, Mourvillier B, et al; Outcomerea Study Group. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis. 2005;41:1224-31.
22. DeRyke CA, Lodise TP, Rybak MJ, Mckinnon PS. Epidemiology, treatment and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest. 2005;128:1414-22.
23. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2006;25:181-5.
24. Kollef MH, Ward S, Sherman G, Prentice D, Schaiff R, Huey W, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med. 2000;28:3456-64.
25. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-55.
26. Romero J, Rubio M, Fernández C, Picazo JJ. Mortality associated with nosocomial bacteriemia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 1995;21:1417-23.
27. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus. Arch Intern Med. 2000;160:1001-4.
28. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment of outcome of Staphylococcus aureus bacteremia. A prospective study of 278 cases. Arch Inter Med. 2002;162:25-32.
29. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36:1418-23.
30. Gómez J, Casas I, Ruiz J, Campillo V, Pérez B, Sánchez F. Bacteriemias por Staphylococcus aureus en un hospital general. An Med Interna. 1990;7:133-7.
31. Mylotte JM, Tayara A. Staphylococcus aureus bacteremia: predictors of 30 day-mortality in a large cohort. Clin Infect Dis. 2000;31:1170.
32. Levine DP, Fromm BS, Ramesh RB. Slow response to vancomycin or vancomycin plus rifampicin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115: 674-80.
33. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448-51.
34. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12 Suppl 1:16-23.
35. Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J. 2005;35 Suppl 2: S136-40.
36. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis. 2004 15;39:539-45.
37. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic and therapeutic odyssey. Clin Infect Dis. 2005;40: 562-73.
38. Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis. 2005;24:826-31.